153 related articles for article (PubMed ID: 34705847)
1. Profile of Medicaid enrollees with sickle cell disease: A high need, high cost population.
Grady A; Fiori A; Patel D; Nysenbaum J
PLoS One; 2021; 16(10):e0257796. PubMed ID: 34705847
[TBL] [Abstract][Full Text] [Related]
2. Age-related prescription medication utilization for the -management of sickle cell disease among Texas Medicaid patients.
Shukla N; Barner JC; Lawson KA; Rascati KL
J Opioid Manag; 2021; 17(4):301-310. PubMed ID: 34533824
[TBL] [Abstract][Full Text] [Related]
3. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
Kang HA; Barner JC
J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
[No Abstract] [Full Text] [Related]
4. Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease.
Kayle M; Valle J; Paulukonis S; Holl JL; Tanabe P; French DD; Garg R; Liem RI; Badawy SM; Treadwell MJ
Pediatr Blood Cancer; 2020 May; 67(5):e28152. PubMed ID: 32147964
[TBL] [Abstract][Full Text] [Related]
5. Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.
Blinder MA; Duh MS; Sasane M; Trahey A; Paley C; Vekeman F
J Emerg Med; 2015 Oct; 49(4):513-522.e1. PubMed ID: 25910824
[TBL] [Abstract][Full Text] [Related]
6. Health Care Burden Associated with Outpatient Opioid Use Following Inpatient or Outpatient Surgery.
Brummett CM; England C; Evans-Shields J; Kong AM; Lew CR; Henriques C; Zimmerman NM; Pawasauskas J; Oderda G
J Manag Care Spec Pharm; 2019 Sep; 25(9):973-983. PubMed ID: 31313621
[TBL] [Abstract][Full Text] [Related]
7. A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective.
DeMartino P; Haag MB; Hersh AR; Caughey AB; Roth JA
JAMA Pediatr; 2021 Jun; 175(6):617-623. PubMed ID: 33749717
[TBL] [Abstract][Full Text] [Related]
8. Influenza vaccination rates and hospitalizations among Medicaid enrollees with and without sickle cell disease, 2009-2015.
Payne AB; Adamkiewicz TV; Grosse SD; Steffens A; Shay DK; Reed C; Schieve LA
Pediatr Blood Cancer; 2021 Dec; 68(12):e29351. PubMed ID: 34542932
[TBL] [Abstract][Full Text] [Related]
9. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
[TBL] [Abstract][Full Text] [Related]
10. The cost of health care for children and adults with sickle cell disease.
Kauf TL; Coates TD; Huazhi L; Mody-Patel N; Hartzema AG
Am J Hematol; 2009 Jun; 84(6):323-7. PubMed ID: 19358302
[TBL] [Abstract][Full Text] [Related]
11. Opioid Use Among Children and Adults With Sickle Cell Disease in North Carolina Medicaid Enrollees in the Era of Opioid Harm Reduction.
Crego N; Douglas C; Bonnabeau E; Eason K; Earls M; Tanabe P; Shah N
J Pediatr Hematol Oncol; 2024 May; 46(4):181-187. PubMed ID: 38551912
[TBL] [Abstract][Full Text] [Related]
12. A Qualitative Analysis of State Medicaid Coverage Benefits for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Sickle Cell Disease (SCD).
Mupfudze TG; Preussler JM; Sees JA; SanCartier M; Arnold SD; Devine S
Transplant Cell Ther; 2021 Apr; 27(4):345-351. PubMed ID: 33836889
[TBL] [Abstract][Full Text] [Related]
13. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
14. Surveillance for Sickle Cell Disease - Sickle Cell Data Collection Program, Two States, 2004-2018.
Snyder AB; Lakshmanan S; Hulihan MM; Paulukonis ST; Zhou M; Horiuchi SS; Abe K; Pope SN; Schieve LA
MMWR Surveill Summ; 2022 Oct; 71(9):1-18. PubMed ID: 36201430
[TBL] [Abstract][Full Text] [Related]
15. Emergency Department Visits and Inpatient Admissions Associated with Priapism among Males with Sickle Cell Disease in the United States, 2006-2010.
Dupervil B; Grosse S; Burnett A; Parker C
PLoS One; 2016; 11(4):e0153257. PubMed ID: 27078839
[TBL] [Abstract][Full Text] [Related]
16. Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999-2007.
Yusuf HR; Atrash HK; Grosse SD; Parker CS; Grant AM
Am J Prev Med; 2010 Apr; 38(4 Suppl):S536-41. PubMed ID: 20331955
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries.
Desai RJ; Mahesri M; Globe D; Mutebi A; Bohn R; Achebe M; Levin R; Schneeweiss S
Ann Hematol; 2020 Nov; 99(11):2497-2505. PubMed ID: 32869184
[TBL] [Abstract][Full Text] [Related]
18. The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization.
Carroll CP; Haywood C; Fagan P; Lanzkron S
Am J Hematol; 2009 Oct; 84(10):666-70. PubMed ID: 19743465
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries.
Jiao B; Johnson KM; Ramsey SD; Bender MA; Devine B; Basu A
Blood Adv; 2023 Jul; 7(13):3276-3283. PubMed ID: 36929166
[TBL] [Abstract][Full Text] [Related]
20. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
Shah NR; Bhor M; Latremouille-Viau D; Kumar Sharma V; Puckrein GA; Gagnon-Sanschagrin P; Khare A; Kumar Singh M; Serra E; Davidson M; Xu L; Guerin A
J Med Econ; 2020 Nov; 23(11):1345-1355. PubMed ID: 32815766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
